Optex Systems Holdings Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Optex Systems Holdings Inc. on February 27, 2012, covering events occurring on February 21 and February 22, 2012. The filing details a private placement of common stock and a related waiver of preferred stock dividends.
Key Financial Metrics
- Capital Raised: $50,000 from the sale of 5,000,000 restricted shares of Common Stock at $0.01 per share.
- Use of Proceeds: Funds are designated for operating expenses.
- Dividend Waiver: Holders of Series A Preferred Stock waived $212,952 in accrued and outstanding dividends, plus rights to future dividends.
- Conversion Price Reset: The conversion price for Series A Preferred Stock was automatically reset to $0.01 per share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, total debt, or liquidity positions beyond the specific transaction details.
Material Changes
The primary material change is the issuance of 5,000,000 new shares of Common Stock to Alpha Capital Anstalt. Additionally, the capital structure was altered by the automatic reset of the Series A Preferred Stock conversion price and the complete waiver of $212,952 in accrued dividends by preferred shareholders.
Outlook, Risks, and Unusual Items
Unusual Items: The transaction involved a significant waiver of accrued dividends ($212,952) by preferred shareholders as an inducement for the common stock purchase. The stock was sold at a negotiated price of $0.01 per share, matching the market price on the negotiation date.
Risks/Contingencies: The issued Common Stock is restricted from resale and bears a restrictive legend, as the transaction was exempt from registration under Section 4(2) of the Securities Act of 1934.
Investor Verification Checklist
- Verify the impact of the 5,000,000 new shares on existing shareholder dilution.
- Confirm the current status of the Series A Preferred Stock conversion rights following the price reset to $0.01.
- Assess the company's liquidity position given the $50,000 infusion is earmarked for operating expenses.
- Review the "Second Waiver" (Exhibit 10.37) to confirm the permanent nature of the dividend waiver.